Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward

Kriti Mittal; Monika Joshi

doi:10.1016/j.medj.2024.10.018

Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward

Med. 2024 Dec 13;5(12):1449-1451. doi: 10.1016/j.medj.2024.10.018.

Authors

Kriti Mittal¹, Monika Joshi²

Affiliations

¹ University of Massachusetts Medical Center, Worcester, MA, USA.
² Penn State Cancer Institute, Hershey, PA, USA. Electronic address: mjoshi@pennstatehealth.psu.edu.

PMID: 39674168
DOI: 10.1016/j.medj.2024.10.018

Abstract

The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation.¹ In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / immunology
Carcinoma, Transitional Cell* / pathology
Carcinoma, Transitional Cell* / therapy
Disease-Free Survival
Humans
Immunotherapy* / methods
Perioperative Care / methods
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / immunology
Urinary Bladder Neoplasms* / pathology
Urinary Bladder Neoplasms* / therapy

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological